These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8996154)

  • 1. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
    Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
    J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
    Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
    N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.
    Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M
    Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
    Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
    Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.
    Okudela K; Hayashi H; Ito T; Yazawa T; Suzuki T; Nakane Y; Sato H; Ishi H; KeQin X; Masuda A; Takahashi T; Kitamura H
    Am J Pathol; 2004 Jan; 164(1):91-100. PubMed ID: 14695323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
    Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
    Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
    Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
    J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
    Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
    Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
    Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
    J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.